RNS Number : 8068V
Genedrive PLC
19 April 2021

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED IN REGULATION (EU) NO 596/2014 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL OF 16 APRIL 2014 ON MARKET ABUSE (MARKET ABUSE REGULATION) AS RETAINED AS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 AS AMENDED.

genedrive plc
("genedrive" or the "Company")

Genedrive successful in PHE National Framework Agreement for Diagnostics Goods and Services

genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces it has been successful with its tender into Public Health England ("PHE") under Lot 1 of the National Microbiology Framework (Diagnostic Goods and Services).

The PHE tender was opened in November 2020 and sought to appoint suppliers to a multi-lot national microbiology framework agreement relating to the supply of Diagnostics Goods and Services and covering Clinical Laboratory Diagnostic Testing Services.

The award of a framework contract is not exclusive to the Company, nor a guarantee of orders, however it does allow participating authorities to issue call-off orders for products in the future. All of genedrive's currently available and CE marked products fall within the framework agreement: Genedrive® 96 SARS-CoV-2 Kit, Genedrive® HCV ID Kit, Genedrive® MT-RNR1 ID Kit

David Budd, CEO of genedrive plc, said: *"We are very pleased to have received notice of this contract award decision and look forward to the opportunity to engage with PHE and relevant authorities on future potential contracts. This is an early notification of the decision and we will update shareholders when we have more information on what this contract may mean for orders and revenues".*

For further details please contact:

genedrive plc +44 (0)161 989 0245
David Budd: CEO / Matthew Fowler: CFO

Peel Hunt LLP (Nominated Adviser and Joint Broker)
James Steel / Victoria Erskine
+44 (0)20 7418 8900

finnCap (Joint Broker)
Geoff Nash / Kate Bannatyne / Alice Lane
+44 (0)20 7220 0500

Walbrook PR Ltd (Media & Investor Relations)
Paul McManus / Anna Dunphy
+44 (0)20 7933 8780 or genedrive@walbrookpr.com
+44 (0)7980 541 893 / +44 (0)7876 741 001

About genedrive plc (http://www.genedriveplc.com)
genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company has assays on market for the detection of HCV, certain military biological targets, and has tests in development for tuberculosis (mTB). The Company recently released a high throughput SARS-CoV-2 assay and has in development a Genedrive® Point of Care version of the assay, both based on Genedrive® chemistry.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

AGRBRGDSRXBDGBI